Chatzipanagiotou Odysseas P, Tsilimigras Diamantis I, Catalano Giovanni, Ruzzenente Andrea, Aldrighetti Luca, Weiss Matthew, Bauer Todd W, Alexandrescu Sorin, Poultsides George A, Maithel Shishir K, Marques Hugo P, Martel Guillaume, Pulitano Carlo, Shen Feng, Cauchy François, Koerkamp Bas Groot, Endo Itaru, Kitago Minoru, Pawlik Timothy M
Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Department of Surgery, University of Verona, Verona, Italy.
J Surg Oncol. 2024 Oct;130(5):1042-1050. doi: 10.1002/jso.27806. Epub 2024 Aug 13.
An elevated platelet count may reflect neoplastic and inflammatory states, with cytokine-driven overproduction of platelets. The objective of this study was to evaluate the prognostic utility of high platelet count among patients undergoing curative-intent liver surgery for intrahepatic cholangiocarcinoma (ICC).
An international, multi-institutional cohort was used to identify patients undergoing curative-intent liver resection for ICC (2000-2020). A high platelet count was defined as platelets >300 *10/L. The relationship between preoperative platelet count, cancer-specific survival (CSS), and overall survival (OS) was examined.
Among 825 patients undergoing curative-intent resection for ICC, 139 had a high platelet count, which correlated with multifocal disease, lymph nodes metastasis, poor to undifferentiated grade, and microvascular invasion. Patients with high platelet counts had worse 5-year (35.8% vs. 46.7%, p = 0.009) CSS and OS (24.8% vs. 39.8%, p < 0.001), relative to patients with a low platelet count. After controlling for relevant clinicopathologic factors, high platelet count remained an adverse independent predictor of CSS (HR = 1.46, 95% CI 1.02-2.09) and OS (HR = 1.59, 95% CI 1.14-2.22).
High platelet count was associated with worse tumor characteristics and poor long-term CSS and OS. Platelet count represents a readily-available laboratory value that may preoperatively improve risk-stratification of patients undergoing curative-intent liver resection for ICC.
血小板计数升高可能反映肿瘤和炎症状态,由细胞因子驱动血小板过度生成。本研究的目的是评估高血小板计数在接受根治性肝切除术治疗肝内胆管癌(ICC)患者中的预后价值。
采用国际多机构队列研究,纳入接受根治性肝切除术治疗ICC的患者(2000 - 2020年)。高血小板计数定义为血小板>300×10⁹/L。研究术前血小板计数与癌症特异性生存(CSS)和总生存(OS)之间的关系。
在825例接受根治性切除术治疗ICC的患者中,139例血小板计数高,这与多灶性疾病、淋巴结转移、低分化至未分化分级以及微血管侵犯相关。与血小板计数低的患者相比,血小板计数高的患者5年CSS(35.8%对46.7%,p = 0.009)和OS(24.8%对39.8%,p < 0.001)更差。在控制相关临床病理因素后,高血小板计数仍然是CSS(HR = 1.46,95%CI 1.02 - 2.09)和OS(HR = 1.59,95%CI 1.14 - 2.22)的不良独立预测因素。
高血小板计数与更差的肿瘤特征以及不良的长期CSS和OS相关。血小板计数是一个易于获得的实验室值,可能有助于术前改善接受根治性肝切除术治疗ICC患者的风险分层。